AMR Roundtable: Optimism About CARB-X's Success And Prospects For The Future (Part 2)
The Pink Sheet spoke with CEOs of Zavante and Amplyx as well as a BARDA official during a roundtable discussion at the recent BIO convention about incentives for antibiotic and antifungal drug development, including a lengthy discussion of the US BARDA's CARB-X accelerator, including ideas for expanding geographically and by product type.
You may also be interested in...
Finance Watch: CARB-X Refills Coffers To Help Biopharmas Fight Resistant Bacteria
Private Company Edition: The global accelerator has new commitments from HHS and the Wellcome Trust. Also, Apollo buys into Sofinnova Partners with an up to €1bn investment, Castle Creek raised $124.6m in private funding this year in lieu of an IPO and Remix closed a $70m series B round.
Finance Watch: 2020 Is Four Biopharma IPOs Away From Matching 2019
With 46 initial public offerings in the US by drug developers so far – including recent launches by Kymera, Inhibrx and Harmony – 2020 will easily beat last year’s 50 IPOs. In follow-on offerings and VC deals, newly public Schrodinger raised $346.5m and Tango’s $50m equity financing.
UK R&D Centre for Antimicrobial Resistance Goes Into Battle
The UK's recently launched AMR Centre has launched two R&D collaborations and plans two more this year.